Arcturus receives $63.2M BARDA award to develop self-amplifying mRNA pandemic flu vaccine

Arcturus Therapeutics Holdings Inc.

BARDA provides up to $63.2 million over three years for pandemic influenza vaccine development using STARR self-amplifying mRNA platform.
Funding covers preclinical through Phase 1 clinical studies, including manufacturing and regulatory support.
Candidate is lower-dose, freeze-dried vaccine; Arcturus' platform has been administered to over 10,000 individuals for SARS-CoV-2.
Contract is terminable by BARDA at any time for convenience; no purchase of vaccine in scope.
Award part of U.S. government's National Strategy for Pandemic Influenza to bolster pandemic preparedness.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.